The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for adults with chronic obstructive pulmonary disease (COPD) who continue to struggle ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

These drugs inhibit interleukin (IL)-5, while Dupixent inhibits IL-4 and IL-13, but can be considered a rival because it is also an injection. Patients may opt to take the others because of their ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Dupixent (dupilumab ... The IL-4 and IL-13 targeting antibody is administered as a subcutaneous injection every other week after an initial loading dose, and can be used with or without topical ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising ... formulation requiring less frequent injections. Following FDA approval in August ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) succeeded in taking the fight to Roche by decreasing the number of annual injections. The company’s other growth driver, Dupixent, is also doing ...